Special Report: Along with its near-term FSGS opportunity, the company is still fully committed to developing its DMX-200 treatment for … Read More
The post Dimerix chief Nina Webster on the potential multi-billion dollar market for DXB’s FSGS kidney treatment appeared first on Stockhead.
Barry Stroman was a reporter for Zerg Watch, before becoming the lead editor. Barry has previously worked for Wired, MacWorld, PCWorld, and VentureBeat covering countless stories concerning all things related to tech and science. Barry studied at NYU.